Taplucainium
- Generic Name
- Taplucainium
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough
Phase 2
Recruiting
- Conditions
- Refractory or Unexplained Chronic Cough
- Interventions
- Other: Placebo
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Nocion Therapeutics
- Target Recruit Count
- 325
- Registration Number
- NCT06504446
- Locations
- 🇺🇸
G & L Research, LLC, Foley, Alabama, United States
🇺🇸AMR Phoenix, Tempe, Arizona, United States
🇺🇸Little Rock Allergy & Asthma, P.A. Clinical Research Center, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath